Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Psyence BiomedicalPBM +9.64%14 Earnings per Share (Diluted) is $-12.56 as of Mar. 2026. GuruFocus rates PBM with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 1,158 Biotechnology companies, Psyence Biomedical ranks better than 94.91% on this metric.
Psyence Biomedical's EPS (Basic) for the
six
months ended in Mar. 2026 was $-0.81.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-12.56.
During the past 6 years, Psyence Biomedical's highest 3-Year average EPS without NRI Growth Rate was 77.60% per year. The lowest was 77.60% per year. And the median was 77.60% per year.
Psyence Biomedical (NAS:PBM) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Psyence Biomedical Earnings per Share (Diluted) Related Terms
Psyence Biomedical Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Psyence Biomedical's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Psyence Biomedical Earnings per Share (Diluted) Chart
PBM vs NRSN, PLUR, CALC: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, Psyence Biomedical's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Psyence Biomedical PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Psyence Biomedical's PE Ratio distribution charts can be found below:
* The bar in red indicates where Psyence Biomedical's PE Ratio falls into.
Psyence Biomedical Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Psyence Biomedical's Earnings Per Share (Diluted) for the fiscal year that ended in Mar. 2026 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-12.56
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-12.56 mean?
Psyence Biomedical (PBM) has a Earnings per Share (Diluted) of $-12.56 as of Mar. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Psyence Biomedical and its competitors. According to the industry distribution chart, Psyence Biomedical ranks #59 out of 1158 companies in the Biotechnology industry, placing it in the top 5.1%.
Is Psyence Biomedical's Earnings per Share (Diluted) too high?
Psyence Biomedical's current Earnings per Share (Diluted) is $-12.56. Based on the distribution chart, Psyence Biomedical ranks #59 out of 1158 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Psyence Biomedical has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Psyence Biomedical's Earnings per Share (Diluted) compare to NRSN and PLUR?
According to the Biotechnology industry distribution chart, Psyence Biomedical ranks #59 out of 1158 companies for Earnings per Share (Diluted). This places Psyence Biomedical in the top 5% of its industry — outperforming the majority of peers. The industry median Earnings per Share (Diluted) is 15.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 15.95, based on 1,158 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Psyence Biomedical and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Psyence Biomedical's current Earnings per Share (Diluted) is $-12.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Psyence Biomedical stock overvalued right now?
Psyence Biomedical (PBM) has a current Earnings per Share (Diluted) of $-12.56. The current Earnings per Share (Diluted) is $-12.56. Psyence Biomedical's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Psyence Biomedical (PBM), the current Earnings per Share (Diluted) is $-12.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
14GF Score
Get the complete analysis for PBM
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBM has been successfully added to your 
